Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo for IVIG Clear all

Conditions: Middle East Respiratory Syndrome Coronavirus
Interventions: SAB-301, Normal (9%) Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Aging
Interventions: Sham, Therapeutic Plasma Exchange, IVIG; Device · Drug
Lead sponsor: Dobri Kiprov; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Mill Valley, California

Conditions: Influenza
Interventions: Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions: Xembify, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more

Conditions: Hypogammaglobulinemia, Congenital Heart Disease
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 6 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions: CMV hyperimmune globulin, Placebo; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
Interventions: Panzyga IVIG, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Stiff-Person Syndrome
Interventions: Intravenous Immunoglobulins, Human, Placebos; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions: Intravenously administered pooled human immunoglobulin (IVIG); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: riliprubart, Placebo, IVIg; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 32
States / cities: Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 6
States / cities: New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Myasthenia Gravis, Generalized
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more

Conditions: Guillain-Barre Syndrome
Interventions: Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg); Drug
Lead sponsor: Chafic Karam; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postural Tachycardia Syndrome
Interventions: IVIG, Albumin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dry Eye
Interventions: Intravenous Immune Globulin (IVIG), Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Mild Cognitive Impairment
Interventions: NewGam 10% IVIG, Placebo; Drug · Other
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Sickle Cell Disease, Pain
Interventions: Immune Globulin Intravenous (IVIG), Normal saline; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 6 Years to 13 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: COVID, SARS-CoV2 Infection, Covid19
Interventions: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo; Biological · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Tucson, Arizona • Mather, California • Palo Alto, California + 13 more

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Post-bypass Prophylactic IVIG in Infants and Neonates

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

IVIG for Infection Prevention After CAR-T-Cell Therapy

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

IVIG - West Nile Encephalitis: Safety and Efficacy

Phase 3 IGIV, 10% in Alzheimer´s Disease

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

IVIG (Gamunex-C) Treatment Study for POTS Subjects

IVIG-eye Drops Treatment for Dry Eye Disease

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

Intravenous Gammaglobulin for Sickle Cell Pain Crises

Outpatient Treatment With Anti-Coronavirus Immunoglobulin